US Anxiety Medication Use Surges Amidst Debate
Analysis based on 8 articles · First reported Feb 23, 2026 · Last updated Mar 01, 2026
The increased use of anxiety medications, particularly SSRIs like Escitalopram, Fluoxetine, and Sertraline, suggests a growing market for pharmaceutical companies in the mental health sector. However, negative statements from government officials like Robert F. Kennedy Jr. and Marty Makary regarding potential harms and addiction risks could introduce regulatory scrutiny and public skepticism, potentially impacting stock prices of companies producing these drugs and increasing demand for alternative treatments like benzodiazepines and beta-blockers.
The proportion of American adults taking anxiety medications, including SSRIs like Escitalopram, Fluoxetine, and Sertraline, has significantly increased from 11.7% in 2019 to 14.3% in 2024, totaling approximately 38 million people. This rise is particularly notable among young adults and is attributed to factors such as the COVID-19 pandemic, increased social media use, isolation, and economic uncertainty. While medical professionals like Patrick Kelly and Emily Wood affirm the safety and efficacy of SSRIs for anxiety disorders, government officials such as Robert F. Kennedy Jr. and Marty Makary have raised concerns about their potential for addiction, links to violent behavior, and adverse effects during pregnancy. This has sparked a debate between medical consensus and public health warnings, with some advocating for lifestyle changes and talk therapy as alternatives or complements to medication. The ease of access to these medications, including through telehealth, and the influence of social media on self-diagnosis are also contributing factors to this trend.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard